UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Increases Stake in Vera Therapeutics, Inc. (NASDAQ:VERA)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 30.1% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 80,106 shares of the company's stock after purchasing an additional 18,532 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.13% of Vera Therapeutics worth $3,388,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in VERA. Avoro Capital Advisors LLC boosted its position in shares of Vera Therapeutics by 30.2% during the 4th quarter. Avoro Capital Advisors LLC now owns 5,610,000 shares of the company's stock valued at $237,247,000 after acquiring an additional 1,300,410 shares during the last quarter. Vestal Point Capital LP bought a new position in shares of Vera Therapeutics during the 4th quarter valued at approximately $45,462,000. Lord Abbett & CO. LLC boosted its position in shares of Vera Therapeutics by 170.8% during the 4th quarter. Lord Abbett & CO. LLC now owns 1,153,670 shares of the company's stock valued at $48,788,000 after acquiring an additional 727,656 shares during the last quarter. Federated Hermes Inc. boosted its position in shares of Vera Therapeutics by 162.2% during the 4th quarter. Federated Hermes Inc. now owns 1,085,986 shares of the company's stock valued at $45,926,000 after acquiring an additional 671,881 shares during the last quarter. Finally, Integral Health Asset Management LLC boosted its position in shares of Vera Therapeutics by 130.0% during the 4th quarter. Integral Health Asset Management LLC now owns 1,150,000 shares of the company's stock valued at $48,634,000 after acquiring an additional 650,000 shares during the last quarter. 99.21% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on the company. Scotiabank reiterated an "outperform" rating on shares of Vera Therapeutics in a research report on Tuesday. Guggenheim restated a "buy" rating on shares of Vera Therapeutics in a report on Tuesday. JPMorgan Chase & Co. decreased their price target on Vera Therapeutics from $77.00 to $71.00 and set an "overweight" rating on the stock in a report on Tuesday, March 4th. Cantor Fitzgerald decreased their price target on Vera Therapeutics from $107.00 to $100.00 and set an "overweight" rating on the stock in a report on Wednesday, May 7th. Finally, Wedbush decreased their price target on Vera Therapeutics from $34.00 to $26.00 and set a "neutral" rating on the stock in a report on Wednesday, May 7th. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the company's stock. According to MarketBeat, Vera Therapeutics has a consensus rating of "Buy" and an average price target of $65.00.

Vera Therapeutics Trading Down 25.9%

VERA stock traded down $7.93 during midday trading on Friday, reaching $22.70. The company's stock had a trading volume of 12,635,089 shares, compared to its average volume of 924,984. The company has a debt-to-equity ratio of 0.17, a quick ratio of 13.76 and a current ratio of 13.76. The stock has a fifty day simple moving average of $22.40 and a two-hundred day simple moving average of $31.60. Vera Therapeutics, Inc. has a 1 year low of $18.53 and a 1 year high of $51.61. The firm has a market capitalization of $1.45 billion, a price-to-earnings ratio of -8.70 and a beta of 1.13.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.81) earnings per share for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.06). During the same period last year, the firm posted ($0.56) earnings per share. On average, equities research analysts predict that Vera Therapeutics, Inc. will post -2.89 EPS for the current year.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.